- An alternatively spliced form of Met receptor is tumorigenic
-
Lee JH, Gao CF, Lee CC, Kim MD, Vande Woude GF
- KMID: 1098091
- Exp Mol Med.
- 2006 Oct;38(5):565-573.
The Met tyrosine kinase receptor is a widely expressed molecule, which mediates pleiotropic cellular responses following activation by its ligand, hepatocyte growth factor/scatter factor (HGF/SF). Previously, one of the authors... -
- CITED
-
- Close
- SHARE
-
- Close
- Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line
-
Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC
- KMID: 2154283
- Exp Mol Med.
- 2013 Nov;45(11):e64.
Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, has shown promising results as a growth inhibitor of HER2-positive... -
- CITED
-
- Close
- SHARE
-
- Close
- Expressions and Clinical Significances of c-met, c-erbB-2, COX-2, and IL-6 in the Biliary Tract Cancers
-
Joo HH, Song EY, Jin SH, Oh SH, Choi YK
- KMID: 937932
- Korean J Gastroenterol.
- 2007 Dec;50(6):370-378.
BACKGROUND/AIMS: c-met, c-erbB-2, interleukin (IL)-6, and cyclooxygenase (COX)-2 expressions are considered to be implicated in the carcinogenesis and progression of cholangiocarcinoma, but the molecular pathogenesis of cholangiocarcinoma is still... -
- CITED
-
- Close
- SHARE
-
- Close
